Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 50 15 versus MAXZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 50 15 versus MAXZIDE.
CAPOZIDE 50/15 vs MAXZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAPOZIDE 50/15 combines captopril (angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (thiazide diuretic). Captopril inhibits ACE, reducing angiotensin II formation, decreasing aldosterone secretion, and lowering blood pressure. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- cotransporter in distal convoluted tubules.
Maxzide is a combination of triamterene, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal renal tubule, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule. The combination reduces electrolyte disturbances.
Oral, 1 tablet (captopril 50 mg / hydrochlorothiazide 15 mg) once daily. May increase to 2 tablets daily in divided doses if needed.
Hydrochlorothiazide 25 mg / triamterene 37.5 mg orally once daily; may increase to twice daily if needed. Max dose: hydrochlorothiazide 50 mg / triamterene 75 mg daily.
None Documented
None Documented
Captopril: terminal half-life ~2 hours (in patients with normal renal function; prolonged in renal impairment to 21-36 hours). Hydrochlorothiazide: half-life 6-15 hours (mean ~9 hours; prolonged in renal impairment). Clinical context: dosing interval affected by renal function.
Triamterene: terminal half-life is approximately 4-6 hours in healthy individuals, but may be prolonged in renal impairment. Hydrochlorothiazide: terminal half-life is approximately 6-15 hours, and it accumulates in renal dysfunction. The combination product's effective half-life is influenced by both components.
Captopril: renal excretion of unchanged drug and metabolites, primarily in urine (60-75%), with ~20% as unchanged captopril; small amount in feces (5-10%). Hydrochlorothiazide: renal excretion (95% unchanged), <5% via biliary/fecal.
Renal: triamterene and hydrochlorothiazide are primarily excreted by the kidneys. Triamterene is extensively metabolized; about 20-30% of the dose is excreted unchanged in urine, with additional metabolites. Hydrochlorothiazide is excreted unchanged in urine (at least 61% of an oral dose within 24 hours).
Category C
Category C
ACE Inhibitor and Diuretic Combination
Diuretic Combination